Jørn P Lindahl1,2, Anders Hartmann3,4, Svend Aakhus5, Knut Endresen5, Karsten Midtvedt4, Hallvard Holdaas4, Torbjørn Leivestad4, Rune Horneland4, Ole Øyen4, Trond Jenssen4,6. 1. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. j.p.h.lindahl@medisin.uio.no. 2. Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372, Oslo, Norway. j.p.h.lindahl@medisin.uio.no. 3. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 4. Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372, Oslo, Norway. 5. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 6. Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway.
Abstract
AIMS/HYPOTHESIS: Mortality due to cardiovascular disease (CVD), particularly coronary artery disease (CAD), is high in type 1 diabetic patients with end-stage renal disease (ESRD). We aimed to determine whether normoglycaemia, as achieved by successful simultaneous pancreas and kidney (SPK) transplantation, could improve long-term outcomes compared with living donor kidney-alone (LDK) transplantation. METHODS: We studied 486 type 1 diabetic patients with ESRD who underwent a first SPK (n = 256) or LDK (n = 230) transplant between 1983 and 2012 and were followed to the end of 2014. Data were retrieved from the Norwegian Renal Registry and hospital records. Kaplan-Meier plots and multivariate Cox regression, with correction for recipient, donor and transplant factors, were used to examine potential associations between transplant type and all-cause and CVD- and CAD-related mortality. RESULTS: Median follow-up time was 7.9 years (interquartile range 4.3, 12.9). The adjusted HR for CVD-related deaths in SPK recipients compared with LDK recipients was 0.63 (95% CI 0.40, 0.99; p = 0.047), while the HRs for all-cause and CAD-related mortality were 0.81 (95% CI 0.57, 1.16; p = 0.25) and 0.63 (95% CI 0.36, 1.12; p = 0.12), respectively. Compared with the LDK group, SPK recipients were younger and received grafts from younger donors. Cardiovascular mortality was higher in patients transplanted between 1983 and 1999 compared with those who received their grafts in subsequent years. CONCLUSIONS/ INTERPRETATION: In patients with type 1 diabetes and ESRD, SPK transplantation was associated with reduced long-term cardiovascular mortality compared with LDK transplantation.
AIMS/HYPOTHESIS: Mortality due to cardiovascular disease (CVD), particularly coronary artery disease (CAD), is high in type 1 diabeticpatients with end-stage renal disease (ESRD). We aimed to determine whether normoglycaemia, as achieved by successful simultaneous pancreas and kidney (SPK) transplantation, could improve long-term outcomes compared with living donor kidney-alone (LDK) transplantation. METHODS: We studied 486 type 1 diabeticpatients with ESRD who underwent a first SPK (n = 256) or LDK (n = 230) transplant between 1983 and 2012 and were followed to the end of 2014. Data were retrieved from the Norwegian Renal Registry and hospital records. Kaplan-Meier plots and multivariate Cox regression, with correction for recipient, donor and transplant factors, were used to examine potential associations between transplant type and all-cause and CVD- and CAD-related mortality. RESULTS: Median follow-up time was 7.9 years (interquartile range 4.3, 12.9). The adjusted HR for CVD-related deaths in SPK recipients compared with LDK recipients was 0.63 (95% CI 0.40, 0.99; p = 0.047), while the HRs for all-cause and CAD-related mortality were 0.81 (95% CI 0.57, 1.16; p = 0.25) and 0.63 (95% CI 0.36, 1.12; p = 0.12), respectively. Compared with the LDK group, SPK recipients were younger and received grafts from younger donors. Cardiovascular mortality was higher in patients transplanted between 1983 and 1999 compared with those who received their grafts in subsequent years. CONCLUSIONS/ INTERPRETATION: In patients with type 1 diabetes and ESRD, SPK transplantation was associated with reduced long-term cardiovascular mortality compared with LDK transplantation.
Authors: R Horneland; V Paulsen; J P Lindahl; K Grzyb; T J Eide; K Lundin; L Aabakken; T Jenssen; E M Aandahl; A Foss; O Øyen Journal: Am J Transplant Date: 2014-11-13 Impact factor: 8.086
Authors: Christian Morath; Martin Zeier; Bernd Döhler; Jan Schmidt; Peter P Nawroth; Vedat Schwenger; Gerhard Opelz Journal: Clin J Am Soc Nephrol Date: 2010-01-21 Impact factor: 8.237
Authors: J P Lindahl; A Hartmann; R Horneland; H Holdaas; A V Reisæter; K Midtvedt; T Leivestad; O Oyen; T Jenssen Journal: Diabetologia Date: 2013-04-03 Impact factor: 10.122
Authors: A O Ojo; H U Meier-Kriesche; J A Hanson; A Leichtman; J C Magee; D Cibrik; R A Wolfe; F K Port; L Agodoa; D B Kaufman; B Kaplan Journal: Transplantation Date: 2001-01-15 Impact factor: 4.939
Authors: Y F Smets; R G Westendorp; J W van der Pijl; F T de Charro; J Ringers; J W de Fijter; H H Lemkes Journal: Lancet Date: 1999-06-05 Impact factor: 79.321
Authors: Brian Y Young; Jagbir Gill; Edmund Huang; Steven K Takemoto; Bishoy Anastasi; Tariq Shah; Suphamai Bunnapradist Journal: Clin J Am Soc Nephrol Date: 2009-02-06 Impact factor: 8.237
Authors: Hans W Sollinger; Jon S Odorico; Yolanda T Becker; Anthony M D'Alessandro; John D Pirsch Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Aleksandra Kukla; Pedro Ventura-Aguiar; Matthew Cooper; Eelco J P de Koning; David J Goodman; Paul R Johnson; Duck J Han; Didier A Mandelbrot; Martha Pavlakis; Frantisek Saudek; Marie-Christine Vantyghem; Titus Augustine; Michael R Rickels Journal: Am J Kidney Dis Date: 2021-05-14 Impact factor: 11.072
Authors: U G Lange; S Rademacher; N Jahn; H-M Hau; B Zirnstein; R Sucher; K Semmling; P Bobbert; A A Lederer; D Buchloh; L Seidemann; D Seehofer Journal: BMC Nephrol Date: 2021-10-21 Impact factor: 2.388
Authors: Enrique Montagud-Marrahi; Alicia Molina-Andújar; Adriana Pané; Maria José Ramírez-Bajo; Antonio Amor; Enric Esmatjes; Joana Ferrer; Mireia Musquera; Fritz Diekmann; Pedro Ventura-Aguiar Journal: BMJ Open Diabetes Res Care Date: 2020-03